Radivojevic Aleksandra, Abu Jad Anas A, Ravanavena Anvesh, Ravindra Chetna, Igweonu-Nwakile Emmanuelar O, Ali Safina, Paul Salomi, Yakkali Shreyas, Teresa Selvin Sneha, Thomas Sonu, Bikeyeva Viktoriya, Abdullah Ahmed, Balani Prachi
Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.
Behavioral Neurosciences and Psychology, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.
Cureus. 2022 Jul 14;14(7):e26852. doi: 10.7759/cureus.26852. eCollection 2022 Jul.
Coronavirus disease 2019 (COVID-19) has rapidly spread across the globe since December 2019. The spectrum of clinical manifestations of COVID-19 ranges from mild to life-threatening forms. Alteration of hepatic function in COVID-19 is multifactorial. The objective of this systematic review is to assess the relationship between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-induced hepatic dysfunction and the clinical outcome in patients infected with COVID-19. We methodically explored several electronic databases (PubMed, PubMed Central, MEDLINE, and Google Scholar) in April 2022 using focused words and terms of medical subject headings for appropriate studies. We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines for conducting our systematic review. Hepatic dysfunction was identified as elevation of liver function tests (LFTs) above the upper limit of normal. The clinical outcome was described as a combination of mortality, intensive care unit (ICU) transfer, and the need for mechanical ventilation (MV). The initial search yielded a total of 7187 studies. After elimination of duplicates, exclusion of studies based on irrelevant titles and abstracts, comprehensive analysis of full-text formats, and evaluation of quality, a total of 16 studies were eligible to be included in our systematic review. In the 16 selected studies, there were 23,962 patients. The SARS-CoV-2 virus can negatively affect several organ systems by interacting with specific receptors widely expressed in the human body. A multifactorial etiology of hepatic dysfunction is observed in COVID-19. SARS-CoV-2 infection is associated with abnormal LFTs. Significantly higher mortality, ICU admissions, and requirement for MV are associated with LFT alterations. For this reason, patients infected with COVID-19 must have their hepatic function closely monitored.
自2019年12月以来，2019冠状病毒病（COVID-19）已在全球迅速传播。COVID-19的临床表现范围从轻度到危及生命的形式。COVID-19中肝功能改变是多因素的。本系统评价的目的是评估严重急性呼吸综合征冠状病毒2（SARS-CoV-2）引起的肝功能障碍与COVID-19感染患者临床结局之间的关系。2022年4月，我们使用医学主题词的重点词汇和术语，系统地检索了几个电子数据库（PubMed、PubMed Central、MEDLINE和谷歌学术），以查找合适的研究。我们遵循系统评价和Meta分析的首选报告项目（PRISMA）指南进行系统评价。肝功能障碍被定义为肝功能检查（LFTs）高于正常上限。临床结局被描述为死亡率、重症监护病房（ICU）转诊和机械通气（MV）需求的综合情况。初步检索共获得7187项研究。在剔除重复项、根据不相关标题和摘要排除研究、对全文格式进行全面分析以及评估质量后，共有16项研究符合纳入我们系统评价的条件。在16项选定的研究中，共有23962名患者。SARS-CoV-2病毒可通过与人体广泛表达的特定受体相互作用，对多个器官系统产生负面影响。在COVID-19中观察到肝功能障碍的多因素病因。SARS-CoV-2感染与LFTs异常有关。LFTs改变与显著更高的死亡率、ICU入院率和MV需求相关。因此，必须密切监测COVID-19感染患者的肝功能。
